---
title: "Entyvio (vedolizumab), all indications: Safety questions"
description: "Safety questions on Entyvio (vedolizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Administration reactions, Side effects, and Vaccines. Questions: Who should not take Entyvio (contraindications)? Can Entyvio cause infusion reactions or allergic reactions? Does Entyvio increase the risk of infections? Does Entyvio require TB testing before starting treatment? 6 further questions follow. 10 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/entyvio/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab), all indications: Safety questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)  
Indication pages: [Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)

## Warnings

<a id="entyvio-contraindications"></a>

### Who should not take Entyvio (contraindications)?

> “ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity 
> reaction to ENTYVIO or any of its excipients (such as dyspnea, bronchospasm, urticaria, 
> flushing, rash and increased heart rate) [see Warnings and Precautions (5.1)].”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

<a id="entyvio-infections"></a>

### Does Entyvio increase the risk of infections?

> “Patients treated with ENTYVIO are at increased risk for developing infections [see Adverse 
> Reactions (6.1)].  Serious infections reported in clinical trials include anal abscess, sepsis 
> (some fatal), tuberculosis (TB), salmonella sepsis, Listeria meningitis, giardiasis, and 
> cytomegaloviral colitis. Postmarketing cases of systemic bacterial, fungal, viral, and parasitic 
> opportunistic infections have been reported.
> Treatment with ENTYVIO should not be initiated in patients with a clinically important 
> active infection until the infection resolves or is adequately treated. In patients with a 
> chronic infection or a history of recurrent infection, consider the risks and benefits prior 
> to prescribing ENTYVIO. During treatment with ENTYVIO, instruct patients to seek medical 
> advice if signs or symptoms of clinically important acute or chronic infection occur. If a 
> serious infection develops or an infection is not responding to standard therapy, monitor the 
> patient closely. ENTYVIO should not be administered until the infection resolves.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

> “In UC Trials I and II and CD Trials I and III, the rate of infections was 0.85 per patient-year in 
> the patients treated with intravenous ENTYVIO and 0.7 per patient-year in the patients treated 
> with placebo [see Warnings and Precautions (5.2)]. The infections consisted primarily of 
> nasopharyngitis, upper respiratory tract infection, sinusitis, and urinary tract infection.
> Two percent of patients discontinued intravenous ENTYVIO due to infections.
> In UC Trials I and II and CD Trials I and III, the rate of serious infections was 0.07 per patient-
> year in patients treated with intravenous ENTYVIO and 0.06 per patient-year in patients 
> treated with placebo. Serious infections were more common in Crohn’s disease patients 
> than ulcerative colitis patients, and anal abscesses were the most frequently reported serious 
> adverse reaction in Crohn’s disease patients. Over 48 months, there was no increase in the 
> rate of serious infections.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

Note: The trial rates pool the ulcerative colitis and Crohn's disease trials.

<a id="entyvio-tb-testing"></a>

### Does Entyvio require TB testing before starting treatment?

> “Consider evaluating patients for TB infection prior to initiating treatment with ENTYVIO. 
> Treatment with ENTYVIO should not be administered to patients with active TB infection. 
> Initiate treatment of latent TB prior to administering ENTYVIO. Consider anti-TB therapy 
> prior to initiation of ENTYVIO in patients with a past history of latent or active TB in whom 
> an adequate course of treatment cannot be confirmed. Monitor patients for signs and 
> symptoms of active TB during and after ENTYVIO treatment.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

> “In clinical trials, all patients were screened for tuberculosis. One case of latent, pulmonary 
> tuberculosis was diagnosed during the controlled trials with intravenous ENTYVIO. Additional 
> cases of pulmonary tuberculosis were diagnosed during the open-label trial. All of these 
> observed cases occurred outside the United States (U.S.), and none of the patients had 
> extrapulmonary manifestations.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

<a id="entyvio-pml"></a>

### Can Entyvio cause PML (progressive multifocal leukoencephalopathy)?

> “PML, a rare and often fatal opportunistic infection of the central nervous system (CNS), 
> has been reported with systemic immunosuppressants, including another integrin receptor 
> antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in 
> patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with 
> multiple contributory factors has been reported in the postmarketing setting (e.g., human 
> immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm3 and prior and 
> concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out.
> Monitor patients on ENTYVIO for any new onset, or worsening, of neurological signs and 
> symptoms. Typical signs and symptoms associated with PML are diverse, progress over 
> days to weeks, and include progressive weakness on one side of the body or clumsiness 
> of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading 
> to confusion and personality changes. The progression of deficits usually leads to death or 
> severe disability over weeks or months. If PML is suspected, withhold dosing with ENTYVIO 
> and refer to a neurologist; if confirmed, discontinue dosing permanently.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

<a id="entyvio-liver"></a>

### Can Entyvio cause liver problems?

> “There have been reports of elevations of transaminase and/or bilirubin in patients receiving 
> ENTYVIO. In general, the combination of transaminase elevations and elevated bilirubin 
> without evidence of obstruction is generally recognized as an important predictor of severe 
> liver injury that may lead to death or the need for a liver transplant in some patients. ENTYVIO 
> should be discontinued in patients with jaundice or other evidence of significant liver injury 
> [see Adverse Reactions (6.1)].”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

> “3 patients reported serious adverse reactions of hepatitis with ENTYVIO; 1 additional case of serious hepatitis was seen in the open-label trial”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=3%20patients%20reported%20serious%20adverse,seen%20in%20the%20open%2Dlabel%20trial)

> “These adverse reactions occurred following 2 to 5 ENTYVIO doses; however, it is unclear if the reactions indicated drug-induced or autoimmune etiology”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=These%20adverse%20reactions%20occurred%20following,indicated%20drug%2Dinduced%20or%20autoimmune%20etiology)

> “All patients recovered following discontinuation of therapy with or without treatment with corticosteroids”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=All%20patients%20recovered%20following%20discontinuation,or%20without%20treatment%20with%20corticosteroids)

> “In controlled trials, the incidence of ALT and AST elevations ≥3x ULN 
> was <2% in patients treated with intravenous ENTYVIO and in patients treated with placebo.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

Note: The hepatitis cases and ALT and AST rates are from the pooled ulcerative colitis and Crohn's disease trials.

## Administration reactions

<a id="entyvio-infusion-reactions"></a>

### Can Entyvio cause infusion reactions or allergic reactions?

> “Infusion-related reactions and hypersensitivity reactions have been reported, including 
> anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure 
> and heart rate [see Adverse Reactions (6.1, 6.2)]. These reactions may occur with the first or 
> subsequent infusions of ENTYVIO and may vary in their time of onset from during infusion 
> or up to several hours post-infusion.
> If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, 
> discontinue administration of ENTYVIO immediately and initiate appropriate treatment.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

> “In UC Trials I and II and CD Trials I and III, one case 
> of anaphylaxis [one out of 1,434 patients treated with intravenous ENTYVIO (0.07%)] was 
> reported by a Crohn’s disease patient during the second infusion (symptoms reported were 
> dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart 
> rate) and was managed with discontinuation of infusion and treatment with antihistamine 
> and intravenous hydrocortisone.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

> “In UC Trials I and II and CD Trials I and III, 4% of patients treated with intravenous ENTYVIO 
> and 3% of patients treated with placebo experienced an infusion-related reaction (IRR). The 
> most frequently observed IRRs in the patients treated with intravenous ENTYVIO (reported 
> more than twice) were nausea, headache, pruritus, dizziness, fatigue, infusion-related 
> reaction, pyrexia, urticaria, and vomiting (each of these adverse reactions occurred in 
> <1% in all patients treated with intravenous ENTYVIO) and no individual adverse reaction 
> reported occurred at a rate above 1%. These reactions generally occurred within the first 
> two hours after the infusion and resolved with no treatment or following antihistamine
> and/or IV hydrocortisone treatment. Less than 1% of patients treated with intravenous 
> ENTYVIO had IRRs assessed by the investigator as severe, and IRRs requiring discontinuation 
> of study treatment occurred in <1%.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

Note: The trial rates pool the ulcerative colitis and Crohn's disease trials.

## Side effects

<a id="entyvio-cancer"></a>

### Was cancer reported in Entyvio clinical trials?

> “In UC Trials I and II and CD Trials I and III, malignancies (excluding dysplasia and basal cell 
> carcinoma) were reported in six of 1,434 (0.4%) patients treated with intravenous ENTYVIO, 
> including colon cancer (n=2), transitional cell carcinoma (n=1), breast cancer (n=1), 
> carcinoid tumor of the appendix (n=1), and squamous cell carcinoma (n=1). Malignancy 
> was reported in one of 297 (0.3%) patients treated with placebo (squamous cell carcinoma).
> Malignancies (excluding dysplasia and basal cell carcinoma) observed during the ongoing 
> open-label long-term extension trial included B-cell lymphoma, breast cancer, colon cancer, 
> malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer 
> of primary neuroendocrine carcinoma, renal cancer, and squamous cell carcinoma. Overall, 
> the number of malignancies in the clinical trials was small; however, long-term exposure 
> was limited.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

Note: The controlled-trial rates pool the ulcerative colitis and Crohn's disease trials.

<a id="entyvio-postmarketing"></a>

### What side effects have been reported with Entyvio since approval?

> “The following adverse reactions have been identified during post-approval use of ENTYVIO. 
> Because these reactions are reported voluntarily from a population of uncertain size, it is 
> not always possible to reliably estimate their frequency or establish a causal relationship 
> to drug exposure.
> Immune system disorders: Anaphylaxis [see Warnings and Precautions (5.1)].
> Gastrointestinal system disorders: Acute pancreatitis.
> Respiratory, thoracic, and mediastinal disorders: Interstitial lung disease, pneumonitis.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

<a id="entyvio-antibodies"></a>

### Do antibodies to Entyvio affect how well it works?

> “The incidence of anti-drug antibodies to intravenous ENTYVIO using a drug-tolerant 
> electrochemiluminescence (ECL) method for patients in UC Trials I and II and CD Trials I 
> and III who had continuous ENTYVIO treatment administered as an intravenous infusion for 
> 52 weeks was 6% (86 out of 1,427 total ENTYVIO-treated patients). Of the 86 patients who 
> tested positive for anti-vedolizumab antibodies, 20 patients were persistently positive (at two 
> or more consecutive study visits) and 56 developed neutralizing antibodies to vedolizumab.
> Among the ENTYVIO-treated patients who developed persistent anti-vedolizumab antibodies, 
> 14/20 patients had serum vedolizumab trough concentrations that were markedly reduced or 
> undetectable and 15/20 patients did not achieve clinical remission at Week 52 in UC Trials I 
> and II and CD Trials I and III. Because of the low occurrence of persistent anti-vedolizumab 
> antibodies (1%; 20/1,427), the effect of these antibodies on the safety and effectiveness of 
> ENTYVIO in these studies has not been fully characterized.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “The incidence of anti-drug antibodies to ENTYVIO using a drug-tolerant ECL method for 
> patients in SC UC Trial and SC CD Trial who had continuous treatment for 52 weeks was 
> 3.4% (13 out of 381 total patients treated with subcutaneous ENTYVIO). Of the 13 patients 
> who tested positive for anti-vedolizumab antibodies, 7 patients were persistently positive 
> (at two or more consecutive study visits) and 7 patients developed neutralizing antibodies 
> to vedolizumab. Two of the 7 patients with Crohn’s disease and none of the 6 patients with 
> ulcerative colitis who had positive anti-vedolizumab antibodies achieved clinical remission 
> at Week 52. There is insufficient data to assess the effect of anti-drug antibodies on 
> pharmacokinetics, effectiveness, and safety of ENTYVIO in the SC UC and SC CD trials.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

Note: Both passages pool the ulcerative colitis and Crohn's disease trials; the second states the ulcerative colitis result separately.

## Vaccines

<a id="entyvio-vaccines"></a>

### Can patients on Entyvio get vaccines, including live vaccines?

> “Prior to initiating treatment with ENTYVIO, all patients should be brought up to date 
> with all immunizations according to current immunization guidelines [see Dosage and 
> Administration (2.1)]. Patients receiving ENTYVIO may receive non-live vaccines (e.g., 
> influenza vaccine injection) and may receive live vaccines if the benefits outweigh the risks. 
> There are no data on the secondary transmission of infection by live vaccines in patients 
> receiving ENTYVIO [see Adverse Reactions (6.1)].”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

> “In a placebo-controlled study of healthy volunteers, 61 subjects were given a single 
> intravenous ENTYVIO 750 mg dose (2.5 times the recommended dose), and 62 subjects 
> received placebo followed by intramuscular vaccination with Hepatitis B surface antigen 
> and oral cholera vaccine. After intramuscular vaccination with three doses of recombinant 
> Hepatitis B surface antigen, those treated with intravenous ENTYVIO did not have lower 
> rates of protective immunity to Hepatitis B virus. However, those exposed to intravenous 
> ENTYVIO did have lower seroconversion rates and anti-cholera titers relative to placebo after 
> receiving the two doses of a killed, oral cholera vaccine. The impact on other oral vaccines 
> and on nasal vaccines in patients is unknown.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

## Related pages
- [Medical information: Entyvio (vedolizumab): All indications](https://www.evicenter.com/medical-information/entyvio)
- [Indication](https://www.evicenter.com/medical-information/entyvio/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/entyvio/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/entyvio/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/entyvio/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio/access-and-coverage)
